Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Visceral Leishmaniasis Market Expected to Grow Between 2025 And 2029?

The market scale for visceral leishmaniasis has experienced robust expansion lately. The market is projected to increase from $1 billion in 2024 to $1.06 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. The historical period growth is mainly due to reasons like a growing disease burden, escalating government financial support, the launch of amphotericin B, the invention of miltefosine, increasing public awareness campaigns, enhanced healthcare accessibility in endemic regions, and formation of public-private alliances.

The market size of visceral leishmaniasis is predicted to see a significant surge in the coming years, reaching$1.32 billion in 2029 with a compound annual growth rate (CAGR) of 5.7%. The anticipated growth within the forecast period can be linked to an upsurge in vaccine development investments, strengthening of global disease monitoring processes, rise in public-private partnerships, better funding for overlooked tropical diseases, and the emergence of gene-based therapies. Noteworthy trends within the forecast period encompass gene editing through clustered regularly interspaced short palindromic repeats (CRISPR), drug discovery propelled by artificial intelligence (AI), drug delivery enriched by nanotechnology, use of next-generation sequencing for parasite assessment, wearable biosensors for early diagnosis, application of blockchain in healthcare supply chain management, utilization of smartphone-based diagnostic tools, and the adoption of three-dimensional (3D) bioprinting for personalized treatment exploration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

What Are the Core Market Drivers Propelling Growth in the Visceral Leishmaniasis Industry?

An increase in malnutrition rates is anticipated to boost the expansion of the visceral leishmaniasis market. Malnutrition, a health issue resulting from insufficient or imbalanced nutrient consumption crucial for proper body operations, is on the rise due to food insecurity. This factor restricts access to nutritious food, causing undernourishment and micronutrient deficiencies, thereby weakening the immunity system. The body becomes more susceptible to infections like visceral leishmaniasis due to the adverse impact of malnutrition on immunity. Shortfalls in nutrients compromise the body’s defense mechanisms, exacerbating the likelihood of serious illness and complications. To illustrate, in July 2024, the Food and Agriculture Organization, a United Nations specialized agency based in Italy, reported that the number of people suffering from undernourishment had increased from 708.7 million in 2021 to 723.8 million in 2022. Thus, the prevalence of malnutrition is contributing to the growth of the visceral leishmaniasis market.

How Is the Visceral Leishmaniasis Market Segmented?

The visceral leishmaniasismarket covered in this report is segmented –

1) By Treatment: Antiparasitic; Antifungal; Other Treatments

2) By Diagnosis Method: Serological Tests; Molecular Tests; Microscopy; Culture Methods

3) By Route Of Administration: Oral; Injectable; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials; Miltefosine; Paromomycin; Sitamaquine; Combination Therapy

2) By Antifungal: Amphotericin B; Liposomal Amphotericin B (AmBisome); Azoles; Echinocandins; Polyenes

3) By Other Treatments: Immunotherapy; Monoclonal Antibodies; Vaccine-Based Approaches; Photodynamic Therapy; Gene Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp

Which Regions Are Driving the Next Phase of the Visceral Leishmaniasis Market Growth?

North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Visceral Leishmaniasis Industry?

Primary enterprises in the visceral leishmaniasis market are shifting their focus towards advancements, such as antiparasitic drugs to boost effectiveness and improve patient accessibility, especially in regions where the disease is prevalent. Antiparasitic drugs, which are used to fight infections from parasites by disrupting their biological functions and growth, reproduction, or survival inside the host body, appear to be the centre of this development. For instance, Zydus Lifesciences Limited, a pharmaceutical firm based in India, earned prequalification approval from the World Health Organization (WHO) in February 2024 for the active pharmaceutical ingredient (API) and formulation of miltefosine, a drug used in the treatment of leishmaniasis or kala-azar. Miltefosine is an orally administered antiparasitic drug that destabilises the parasite’s cell membrane and hampers its metabolism, leading to the parasite’s cell death. It also obstructs the parasite’s growth and survival, making it an effective oral therapy for visceral leishmaniasis or kala azar.

View the full report here:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

How Is the Visceral Leishmaniasis Market Defined and What Are Its Core Parameters?

Visceral leishmaniasis, also known as kala-azar, is a severe parasitic disease caused by Leishmania species, transmitted through infected sandfly bites. It affects internal organs such as the spleen, liver and bone marrow, causing prolonged fever, weight loss, anemia and organ enlargement. If untreated, it can be fatal, making early diagnosis and treatment crucial.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23573

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model